MIT Holding, Inc. (MITD) – A Concierge Medical Service Provider Primed for Home Infusion Market
MIT Holding is a single source provider of concierge medical services and products throughout the United States. Through a portfolio of license, contractual and affiliate agreements, the company offers a portfolio of services that includes but is in no way limited to the:
• Administering of intravenous infusions;
• Management of medical services; and
• Provision of in-home therapies.
In a press release dated April 27, 2015, the company revealed that it had achieved positive net income from its operations in 2014, to the tune of over $14,000. This profit amount signaled significant improvement from the previous year’s numbers. It’s also a direct consequence of the company’s renewed focus on its in-home health recovery business and the resulting growth in overall income generated in 2014 (over $1.1 million).
Many aspects of the structure of MIT Holding’s in-home health recovery business, which facilitates and assists patients from the time of their release from a hospital through to a full in-home recovery, were finalized in 2014. The target audience for the business have been determined to be those needing infusion for recovery.
With many infusion therapies costing more than $10,000 per patient, per year and many patients needing special counseling and education regarding their condition and treatment, there is certainly a market for the business.
The two most recognized names in the infusion sector, CVS Health Corp. (NYSE: CVS) and Walgreen Co. (NYSE: WAG), have established footprints into the home infusion market through a series of strategic acquisitions that highlight the growing demand for home infusion services. The usual retail pharmacies and traditional distributors are generally designed to carry inventories of low cost, high volume products, while MIT Holding’s platform is based on the delivery of high cost, low volume specialty pharmaceuticals that have specialized handling and administration requirements.
Today’s United States home infusion market has been estimated at around $16 billion and is forecasted to reach approximately $27 billion by 2020, according to Harris Williams & Co. At a compound annual growth rate of approximately 9% per year, this could mean a significant market opportunity for MIT Holding. Furthermore, the company is anticipating that the demand for low cost, high quality home care will increase as paying patients become aware that they could realize up to 90% in savings on infusion services performed in the home versus in the hospital and that, as a result, this will result in continued growth for its in-home health recovery business. It is little wonder that this is an area of significant focus in its operations.
For more information, visit the company’s website at www.mitholdinginc.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
MIT Holding is a single source provider of concierge medical services and products throughout the United States. Through a portfolio of license, contractual and affiliate agreements, the company offers a portfolio of services that includes but is in no way limited to the:
• Administering of intravenous infusions;
• Management of medical services; and
• Provision of in-home therapies.
In a press release dated April 27, 2015, the company revealed that it had achieved positive net income from its operations in 2014, to the tune of over $14,000. This profit amount signaled significant improvement from the previous year’s numbers. It’s also a direct consequence of the company’s renewed focus on its in-home health recovery business and the resulting growth in overall income generated in 2014 (over $1.1 million).
Many aspects of the structure of MIT Holding’s in-home health recovery business, which facilitates and assists patients from the time of their release from a hospital through to a full in-home recovery, were finalized in 2014. The target audience for the business have been determined to be those needing infusion for recovery.
With many infusion therapies costing more than $10,000 per patient, per year and many patients needing special counseling and education regarding their condition and treatment, there is certainly a market for the business.
The two most recognized names in the infusion sector, CVS Health Corp. (NYSE: CVS) and Walgreen Co. (NYSE: WAG), have established footprints into the home infusion market through a series of strategic acquisitions that highlight the growing demand for home infusion services. The usual retail pharmacies and traditional distributors are generally designed to carry inventories of low cost, high volume products, while MIT Holding’s platform is based on the delivery of high cost, low volume specialty pharmaceuticals that have specialized handling and administration requirements.
Today’s United States home infusion market has been estimated at around $16 billion and is forecasted to reach approximately $27 billion by 2020, according to Harris Williams & Co. At a compound annual growth rate of approximately 9% per year, this could mean a significant market opportunity for MIT Holding. Furthermore, the company is anticipating that the demand for low cost, high quality home care will increase as paying patients become aware that they could realize up to 90% in savings on infusion services performed in the home versus in the hospital and that, as a result, this will result in continued growth for its in-home health recovery business. It is little wonder that this is an area of significant focus in its operations.
For more information, visit the company’s website at www.mitholdinginc.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
